Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.45
-0.2100-5.74%
Post-market: 3.490.0400+1.16%19:55 EDT
Volume:4.97M
Turnover:17.58M
Market Cap:297.43M
PE:-0.92
High:3.74
Open:3.66
Low:3.42
Close:3.66
52wk High:19.11
52wk Low:3.42
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.51
T/O Rate:8.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.79
PE(LYR):-1.09

Loading ...

EyePoint is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 06

EyePoint price target lowered to $27 from $30 at H.C. Wainwright

TIPRANKS
·
Aug 06

Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile

TIPRANKS
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Aug 06

EyePoint Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss

TradingKey
·
Aug 05

EyePoint reports Q2 EPS ($1.09), consensus (96c)

TIPRANKS
·
Aug 05

EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate

Benzinga Earnings
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

EyePoint Q2 FY26 Net Loss Widens to $94.47 Million; Revenue Drops to $507,000

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Basic EPS USD -1.09

THOMSON REUTERS
·
Aug 05

EyePoint Pharmaceuticals Q2 Product Sales USD 507 Thousand

THOMSON REUTERS
·
Aug 05

EyePoint Completes Enrollment in Phase 3 Duravyu Diabetic Macular Edema Trials COMO, CAPRI

Reuters
·
Jul 30

EyePoint (EYPT) Settles DOJ Claims, Is The 71% Undervaluation Case Convincing?

Simply Wall St.
·
Jul 30

EyePoint - Phase 3 Wet Amd Program Data Anticipated Beginning August 2026

THOMSON REUTERS
·
Jul 30

EyePoint - Topline Data for Dme Phase 3 Trials Anticipated in Q4 2027

THOMSON REUTERS
·
Jul 30

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of Duravyu™ for Treatment of Diabetic Macular Edema (Dme)

THOMSON REUTERS
·
Jul 30